Kathryn oversees the timely preclinical development of drug candidates from discovery to the clinic and subsequent regulatory approval.
Prior to joining Life Edit, Kathryn was an independent consultant and had worked at Avalanche Biotechnologies/Adverum, Affymax, AP Pharma and Pharmacyclics. She has overseen preclinical development for gene therapy, oncology, cardiology, ophthalmology, pain management, anti-infectives, hematology and tissue protection programs.
Kathryn received her PhD in Chemistry and Biochemistry from La Trobe University in Australia with thesis titled ‘‘Synthesis and biological evaluation of porphyrins for use in photodynamic therapy of brain tumors,” after which she completed postdoctoral studies at the University of Toledo and Wayne State University. She has generated eight patents and over sixty manuscripts.